HASNIZA BINTI ZAMAN HURI

HASNIZA BINTI ZAMAN HURI
University of Malaya, Kualalumpur, Malaysia

Biography

Dr Hasniza Zaman Huri obtained her PhD and Master in Clinical Pharmacy from National University of Malaysia and B. Pharm (Honours) from the University of Malaya. She is the founder Dean of Faculty of Pharmacy, a newly established and the 13th faculty in the University of Malaya since 1 September 2019; and an Associate Professor of Clinical Pharmacy and Pharmacogenomics in the Department of Clinical Pharmacy and Pharmacy Practice. She lectures the clinical pharmacy, pharmaceutical biotechnology, and good clinical practice (GCP) modules. Associate Professor Dr Hasniza and Type 2 Diabetes is inseparable. Her research covers optimal management, biomarkers, insulin-resistant study, as well as all areas of type 2 diabetes mellitus, and clinical pharmacy encompasses of associations of drug response and related factors, drug-related problems and pharmaceutical care issues, general biomarkers study, pharmacogenomics-pharmacodynamics study, gene-disease-drug response associations and PK-PD study. She has published more than 65 ISI papers in her area of expertise. She held various critical administrative posts, among others the Manager of Clinical Investigation Centre (CIC) from 2012-2015 and later appointed as the Director/Head of CIC (2015-2019). CIC, University Malaya Medical Centre is a world-class, reputable and multi-winning clinical trial centre. Under her tenure, CIC has won many accolades at the international levels, procured around 590 clinical trials and working with 300 pharmaceutical sponsors and CROs around the globe. CIC recognized as the first Prime Site for Quintiles (now is IQVIA) in Asia, the first Strategic Alliance Site for Parexel Inc in Malaysia and the first Pfizer’s INSPIRE (Investigator Networks, Site Partnerships and Infrastructure for Research Excellence) Site in Malaysia and many more. Previously, Associate Professor Dr Hasniza was also leading the research thrust of UMMC strategic planning. At present, she is also the Honorary Visiting Consultant at CIC and also the permanent member of the Drug Control Authority (DCA) Ministry of Health, Malaysia.